In order to standardize drug clinical trial data on-site verification,
China Food and Drug Administration formulated the "drug clinical trial
data on-site verification points", hereby release and related matters
are announced as follows:
First, China Food and Drug Administration will apply for registration
under "drug clinical trial data on-site verification points", for
complete self-examination information furnished one by one drug clinical
trial data on-site verification.
Second,
some of the drugs clinical trial data from the on-site verification of
the case has been completed, the part of the drug clinical trial
institution exists unauthorized modification of data, data, and data is
not traceable concealed fraud and other issues, China Food and Drug
Administration announced the discovery along together, and The applicant for registration, clinical trials institutions, clinical
trials contract research organizations and related persons responsible
be severely dealt with according to law.
Third,
clinical trials or clinical trials contract research organization
should continue in accordance with the "drug clinical trial data on-site
verification points", the authenticity of test data integrity
self-examination, found unreal problems, countries should take the
initiative to report Food and Drug Administration, and the initiative to urge the applicant to withdraw the application. Clinical trials contract research organization or organizations
proactively report problems, may be exempted from accountability.
Fourth,
the applicant has found that the presence of drug registration clinical
trial data authenticity may be directed to China Food and Drug
Administration for withdrawal. In
the China Food and Drug Administration notice on-site verification of
application is withdrawn before the initiative, publish a list of
applicants and varieties, not to be held accountable; after notification
to accept the withdrawal of the application is no longer on-site
verification.
没有评论:
发表评论